A blood test that can detect mutations in the androgen receptor can predict response to abiraterone in prostate cancer.
A molecular test that can guide providers with treatment choices is a poster child for precision medicine. Researchers from the Institute of Cancer Research in London, through a global collaboration that included scientists at the Weill Cornell College of Medicine in New York, have discovered a gene signature that can identify abiraterone-resistant prostate tumors. The results, published in Science Translational Medicine, predict non-responders to abiraterone and can prove extremely valuable if the discovery holds true in the broader population.
When the researchers sequenced 274 blood samples from 97 prostate cancer patients, they found that mutations in the androgen receptor (AR) gene could predict resistance to the drug abiraterone. This patient population harboring the mutation had poor overall survival.
Abiraterone is standard of care for men with advanced prostate cancer, but 30% to 60% of patients do not respond to the drug. The current research showed that men harboring a mutation in the AR gene or who had an amplification of AR gene, were less likely to see a decrease of more than 90% in their prostate-specific antigen levels. An interesting study finding was that the development of abiraterone resistance was associated with the appearance of either mutation in 15% of the study population, indicative of acquired resistance to the drug. The appearance of the mutated form of the receptor in the patient’s blood is valuable in cancer patients in whom repeat biopsies are not always a feasible option.
“The discovery of abiraterone was an important step forward for patients with advanced prostate cancer, but we know it doesn’t work for all men, and we’ve been searching for a marker that will tell us in advance which men will benefit. We’re delighted to have developed a test that appears to predict very accurately whether a patient will respond to abiraterone, and that it can be performed on blood samples—removing the need to take a biopsy,” said Gerhardt Attard, MD, PhD, one of the senior investigators on the paper.
The authors are now designing a prospective clinical trial to show that men with either mutation in their AR gene would fare better with chemotherapy rather than abiraterone or other drugs in the same class.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More